We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Vertex Pharmaceuticals (VRTX - Free Report) closed at $469.55, marking a +1.15% move from the previous day. The stock's change was more than the S&P 500's daily gain of 0.32%. Meanwhile, the Dow gained 0.53%, and the Nasdaq, a tech-heavy index, added 0.26%.
Coming into today, shares of the drugmaker had gained 5.03% in the past month. In that same time, the Medical sector lost 3.4%, while the S&P 500 gained 4.51%.
Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. The company plans to announce its earnings on August 4, 2025. The company is predicted to post an EPS of $4.25, indicating a 133.13% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $2.89 billion, up 9.23% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $17.81 per share and a revenue of $11.91 billion, indicating changes of +4140.48% and +8.09%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Vertex Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.07% higher within the past month. Vertex Pharmaceuticals currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Vertex Pharmaceuticals is presently being traded at a Forward P/E ratio of 26.07. This signifies a premium in comparison to the average Forward P/E of 17.83 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 83, which puts it in the top 34% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Vertex Pharmaceuticals (VRTX - Free Report) closed at $469.55, marking a +1.15% move from the previous day. The stock's change was more than the S&P 500's daily gain of 0.32%. Meanwhile, the Dow gained 0.53%, and the Nasdaq, a tech-heavy index, added 0.26%.
Coming into today, shares of the drugmaker had gained 5.03% in the past month. In that same time, the Medical sector lost 3.4%, while the S&P 500 gained 4.51%.
Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. The company plans to announce its earnings on August 4, 2025. The company is predicted to post an EPS of $4.25, indicating a 133.13% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $2.89 billion, up 9.23% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $17.81 per share and a revenue of $11.91 billion, indicating changes of +4140.48% and +8.09%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Vertex Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.07% higher within the past month. Vertex Pharmaceuticals currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Vertex Pharmaceuticals is presently being traded at a Forward P/E ratio of 26.07. This signifies a premium in comparison to the average Forward P/E of 17.83 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 83, which puts it in the top 34% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.